期刊
AMERICAN JOURNAL OF MEDICINE
卷 122, 期 6, 页码 25-36出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2009.03.014
关键词
DDP-4 inhibitors; extra-glycemic effects; GLP-1 receptor agonists
资金
- Department of Veteran Affairs.
Impaired insulin secretion plays a major role in the pathogenesis of type 2 diabetes mellitus, and progressive loss of beta-cell function is a pathophysiologic hallmark of type 2 diabetes. Recent science has elaborated on the role of the incretin hormones on beta-cell function and insulin secretion, as well as the role that incretin-based pharmacotherapies may have on glycemic control and beta-cell function, possibly altering the progressive loss of beta-cell function and possibly reversing/halting disease progression. However, incretin-based therapies may also have benefits extending beyond glycemic control and insulin secretion. In this review we examine some of those beyond-glycemic benefits, including presentation of data on weight reduction, blood pressure lowering, beneficial changes in the lipid profile, and improvements in myocardial and endothelial function. We investigate how those effects may help ameliorate the cardiovascular burden in patients with diabetes. (c) 2009 Published by Elsevier Inc. The American Journal of Medicine (2009) 122, S25-S36
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据